Ace Alzheimer Center Barcelona leads Pilot 3 of the COMFORTage project, an interventional study approved in October 2024, targeting individuals with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). The study aims to evaluate the efficacy of digital tools on functional outcomes, primarily cognitive decline, and to assess the impact of biomarkers on this progression. A total of 100 participants will be followed over two years—one year of active cognitive stimulation intervention using digital platforms such as Healthentia, Eligence, and LingGames, followed by one year of follow-up without intervention. Key outcomes include cognitive performance across five neuropsychological domains, quality of life, and physical activity, with continuous data collection throughout 2025 and early 2026.
Title: Integration of multiple sources towards personalised preventions
Partner: ACE
Type: Intervention
Target: MCI & AD
Focus: Eficacy of digital tools on functionality (main ourput cognitive decline) & impact of biomarkers on cognitive decline
Type of prevention targeted:
Objective: Determine impact of cognitive stimulation on cogntive decline after two years of followup
